Shares
Investment in our shares
Investing in BioGaia means becoming a shareholder in a company with a strong and well-established position in a rapidly growing market. Since 1990, BioGaia has been a global pioneer in probiotics, creating value for consumers, partners and shareholders. Our focus is on conducting research into new and existing bacterial strains, developing innovative probiotic products tailored to market needs and boosting sales. Since our initial public offering in 1998, we have continuously strived to run a business that combines growth with stable profitability. Our long-term financial target is to achieve an operating margin (operating profit in relation to sales) of at least 34 percent, while maintaining strong growth. In addition to the current dividend policy of 50 percent of the Group’s profit after tax and after adjustments for non-recurring items, BioGaia intends to pay extra dividends of 50–100 percent of the Group’s profit after tax and after adjustments for non-recurring items in the coming years, provided that future cash flows align with BioGaia’s forecasts.
The main factors that make BioGaia an attractive investment opportunity are summarized below:
Expanding industry
The global market for probiotic supplements is expected to grow by 3–5 percent annually, depending on market estimates, through 2029, driven by an increased focus on health and preventive care[1].
Leading market position
BioGaia is a world leader in probiotic products for children with colic. We strengthen our position by continuously developing and renewing our product range. This strategy involves expanding into new health segments, improving product formulations, and ensuring sustainable production.
Profitable growth
In 2024, BioGaia’s revenue grew by 10 percent, and our average operating margin has been 32 percent over the last five years. This performance has been achieved despite global economic uncertainty, geopolitical tensions and high inflation. We continue to prioritize profitable growth by meeting consumer demands and ensuring cost efficiency.
Innovative products
By investing around 11 percent of our net sales in research and development, we strengthen our competitive advantage. Our focus on innovation has enabled the launch of several groundbreaking products, such as the world’s first probiotic drops and chewable tablets.
Strong brand
BioGaia has evolved from a B2B company to a leading consumer brand in probiotics. Our brand is associated with high quality, reliability and proven science, fostering loyalty among distribution partners, healthcare professionals, and consumers across our markets.
Sustainable solutions
BioGaia aims to be a leader in sustainability, which has resulted in multiple awards and certifications. For example, in 2024 we received HACCP certification for food safety, and all of our paper-based packaging materials are currently sourced from certified sustainable forestry. By prioritizing healthy products, sustainable practices, and a reduced environmental footprint, we generate value for the planet as well as the long-term growth of the company.
Efficient business
A significant portion of our production is managed in-house in Eslöv, ensuring an efficient and profitable manufacturing and delivery process. We continuously work to optimize our production, product range and supply chains through Lean methods and increased automation. With a combination of market leadership, innovation and sustainability, BioGaia is well positioned to continue to deliver value to shareholders and other stakeholders.
[1] Euromonitor, September 2024.
Share structure
See an overview of BioGaia’s share capital development since the company’s formation.
Investor contact
